"Those of us with adrenal disease know the importance of having new treatments that will give us an opportunity to have the best quality of life with improved medical options. Participation in clinical trials can help accelerate the development of new treatments and address our community's unmet medical needs."
--Lori Engler, Executive Director, NADF
CLINICAL RESEARCH STUDY FOR ENDOGENOUS CUSHING SYNROME
The purpose of the Grace Study is to evaluate the effectiveness (benefits) and safety (side effects) of an investigational study medicine, relacorilant, in treating participants with endogenous Cushing syndrome. See details here: https://www.nadf.us/grace-study---endogenous-cushing-syndrome.html
CLINICAL RESEARCH STUDIES FOR ADULTS AND CHILDREN WITH CONGENITAL ADRENAL HYPERPLASIA (CAH)
If you or your child has congenital adrenal hyperplasia, the CAH Studies may be of interest to you. See more information here: https://www.nadf.us/cahtalyst-study-cah.html
A STUDY OF GENE THERAPY FOR CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH)
BridgeBio affiliate, Adrenas Therapeutics, is enrolling adults in a gene therapy trial for classic CAH. See more information here. https://www.nadf.us/gene-therapy-for-classic-cah.html
SPRUCE BIOSCIENCES NOW ENROLLING CAHMELIA CLINICAL TRIAL
Spruce Biosciences, a late-stage clinical development company focused on developing and commercializing novel therapies for rare endocrine disorders, is now enrolling patients with classic CAH into the CAHmelia clinical trials. See more here. https://www.nadf.us/cahmelia-adult-studies-classic-cah.html.
the Spark-PA study for primary aldosteronism
Spark-PA is conducting a clinical research study exploring an investigational therapy (study drug) for people with high blood pressure caused by PA. For more information, visit https://www.nadf.us/primary-aldosteronism-study.html
NADF does not endorse any product, merely informing our members about a new clinical trial.